Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling

Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P‐glycoprotein (P‐gp) transporter. By integrating in silico, preclinical, and clinical pharmacokinetic (PK) findings, minimal and full physiologically based pharmacokinetic (PBPK) models were developed to predict the drug‐drug interaction (DDI) potential for naloxegol. The models reasonably predicted the observed changes in naloxegol exposure with ketoconazole (increase of 13.1‐fold predicted vs. 12.9‐fold observed), diltiazem (increase of 2.8‐fold predicted vs. 3.4‐fold observed), rifampin (reduction of 76% predicted vs. 89% observed), and quinidine (increase of 1.2‐fold predicted vs. 1.4‐fold observed). The moderate CYP3A4 inducer efavirenz was predicted to reduce naloxegol exposure by ∼50%, whereas weak CYP3A inhibitors were predicted to minimally affect exposure. In summary, the PBPK models reasonably estimated interactions with various CYP3A modulators and can be used to guide dosing in clinical practice when naloxegol is coadministered with such agents.

[1]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[2]  K. Bui,et al.  The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol , 2014, Journal of clinical pharmacology.

[3]  Daniel Röshammar,et al.  In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. , 2011, British journal of clinical pharmacology.

[4]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[5]  M. Yamazaki,et al.  Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.

[6]  M. Hutchison,et al.  Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects , 2015, International journal of clinical pharmacology and therapeutics.

[7]  M. Maurin,et al.  Determination of the pKa and pH-solubility behavior of an ionizable cyclic carbamate, (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4- (trifluoromethyl)-2H-3,1-benzoxazin-2-one (DMP 266). , 1996, Pharmaceutical development and technology.

[8]  M. A. Hedaya,et al.  The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers , 2005, Biopharmaceutics & drug disposition.

[9]  X. Ruan.  The Effect of Quinidine, a Strong P‐Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol , 2016, Journal of clinical pharmacology.

[10]  W. Kirch,et al.  P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.

[11]  K. Morrissey,et al.  Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction , 2008, Drug Metabolism and Disposition.

[12]  John A Wagner,et al.  Effect of Different Durations and Formulations of Diltiazem on the Single‐Dose Pharmacokinetics of Midazolam: How Long Do We Go? , 2011, Journal of clinical pharmacology.

[13]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[14]  Diansong Zhou,et al.  Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol , 2016, Journal of clinical pharmacology.

[15]  M. Monshouwer,et al.  Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[16]  Diansong Zhou,et al.  Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents , 2014, Biopharmaceutics & drug disposition.

[17]  H. Bohets,et al.  Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co‐medication interactions , 2000, British journal of pharmacology.

[18]  D. Thakker,et al.  Efflux Ratio Cannot Assess P-Glycoprotein-Mediated Attenuation of Absorptive Transport: Asymmetric Effect of P-Glycoprotein on Absorptive and Secretory Transport Across Caco-2 Cell Monolayers , 2003, Pharmaceutical Research.

[19]  W. Chey,et al.  Naloxegol for opioid-induced constipation in patients with noncancer pain. , 2014, The New England journal of medicine.

[20]  Caroline A. Lee,et al.  Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug , 2009, Clinical pharmacology and therapeutics.

[21]  L. Webster,et al.  A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation , 2013, PAIN®.

[22]  K. Bui,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending‐dose study , 2015, Clinical pharmacology in drug development.

[23]  Ronald T. Borchardt,et al.  Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa? , 2002, Pharmaceutical Research.